Pfizer has been growing its cancer pipeline over the past 5 years .
Checkpoint inhibitors, also known as PD-1 or PD-L1 treatments, can help patients with advanced forms of the disease--but around two-thirds of patients don’t benefit from them. Cocktail therapies may be the only way to help more patients live longer and also try to stop resistance.
This follows the lead of other Big Pharmas and biotechs that are focusing on putting new cancer therapies together.
http://www.fiercebiotech.com/biotech/pfizer-to-trial-triple-threat-cancer-cocktail-therapy
Pfizer in bed with Merck , Merck in bed with VLA
Add to My Watchlist
What is My Watchlist?